PE20251071A1 - Inhibidores de kras - Google Patents
Inhibidores de krasInfo
- Publication number
- PE20251071A1 PE20251071A1 PE2024001867A PE2024001867A PE20251071A1 PE 20251071 A1 PE20251071 A1 PE 20251071A1 PE 2024001867 A PE2024001867 A PE 2024001867A PE 2024001867 A PE2024001867 A PE 2024001867A PE 20251071 A1 PE20251071 A1 PE 20251071A1
- Authority
- PE
- Peru
- Prior art keywords
- methyl
- pharmaceutically acceptable
- relates
- kras inhibitors
- cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invencion se refiere a unos compuestos de la formula donde A es -C(H)- o -N-; B es -C(R4)- o -N-; R1 es H, hidroxilo, metoxi, alquilo C1-4, entre otros; D1 es -CH2-, -CH2CH2- o -CH(CH2CN)-; X es -O- o -S-; Y es -C(CN)-o -N-; Z es -C(R3c)- o -N-; G es -C(R3b)- o -N-; cada R2, R3a, R3b y R3c es independientemente H, metilo o halogeno; R4 es H, metilo, -CH2-OH, entre otros. Tambien se refiere a una composicion farmaceutica que comprende el compuesto en mencion o una sal farmaceuticamente aceptable de este, y un portador, diluyente o excipiente farmaceuticamente aceptable. Estos son inhibidores de KRas y permiten tratar el cancer, como el cancer de pulmon, cancer de pancreas, cancer de cuello uterino, entre otros.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263323607P | 2022-03-25 | 2022-03-25 | |
| US202263406906P | 2022-09-15 | 2022-09-15 | |
| US202263386404P | 2022-12-07 | 2022-12-07 | |
| PCT/US2023/016257 WO2023183585A1 (en) | 2022-03-25 | 2023-03-24 | Kras inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20251071A1 true PE20251071A1 (es) | 2025-04-10 |
Family
ID=86331239
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2024001867A PE20251071A1 (es) | 2022-03-25 | 2023-03-24 | Inhibidores de kras |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US12351591B2 (es) |
| EP (1) | EP4499233A1 (es) |
| JP (2) | JP7676677B2 (es) |
| KR (2) | KR102847563B1 (es) |
| CN (1) | CN119095853A (es) |
| AU (1) | AU2023241055A1 (es) |
| CA (1) | CA3246810A1 (es) |
| CL (1) | CL2024002874A1 (es) |
| CO (1) | CO2024012604A2 (es) |
| DO (1) | DOP2024000186A (es) |
| IL (1) | IL315782A (es) |
| MX (1) | MX2024011631A (es) |
| PE (1) | PE20251071A1 (es) |
| TW (2) | TW202438502A (es) |
| WO (1) | WO2023183585A1 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250109197A (ko) | 2022-11-21 | 2025-07-16 | 트리라인 바이오사이언시스, 인크. | 스피로환식 디하이드로피라노피리미딘 KRas 억제제 |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| US20240343736A1 (en) * | 2023-03-30 | 2024-10-17 | Eli Lilly And Company | Kras inhibitors |
| US20240368193A1 (en) | 2023-03-31 | 2024-11-07 | Eli Lilly And Company | Kras inhibitors |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| TW202515570A (zh) | 2023-08-17 | 2025-04-16 | 美商樹線生物科學公司 | 螺環二氫哌喃并嘧啶ｋｒａｓ抑制劑 |
| WO2025054530A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| TW202528315A (zh) | 2023-09-21 | 2025-07-16 | 美商樹線生物科學公司 | 螺環二氫哌喃并吡啶ＫＲａｓ抑制劑 |
| TW202530228A (zh) | 2023-10-12 | 2025-08-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025092798A1 (zh) * | 2023-10-30 | 2025-05-08 | 江苏恒瑞医药股份有限公司 | 稠合杂芳基类化合物、其制备方法及其在医药上的应用 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025214341A1 (zh) * | 2024-04-08 | 2025-10-16 | 江苏恒瑞医药股份有限公司 | 二氢呋喃并[3,4-f]喹唑啉类化合物、其制备方法及其在医药上的应用 |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025245127A1 (en) | 2024-05-21 | 2025-11-27 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3030582A1 (en) | 2015-07-22 | 2017-01-26 | The Royal Institution For The Advancement Of Learning/Mcgill University | Compounds and uses thereof in the treatment of cancers and other medical conditions |
| SI3710439T1 (sl) | 2017-11-15 | 2023-06-30 | Mirati Therapeutics, Inc., | Zaviralci mutacije kras g12c |
| TW202033518A (zh) * | 2018-10-15 | 2020-09-16 | 美商美國禮來大藥廠 | Kras g12c 抑制劑 |
| WO2020146613A1 (en) | 2019-01-10 | 2020-07-16 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| JP7622043B2 (ja) | 2019-08-29 | 2025-01-27 | ミラティ セラピューティクス， インコーポレイテッド | Ｋｒａｓ ｇ１２ｄ阻害剤 |
| CA3161162A1 (en) | 2019-12-11 | 2021-06-17 | Serge Louis Boulet | Kras g12c inhibitors |
| CA3182507A1 (en) * | 2020-06-04 | 2021-12-09 | Bo Shan | Inhibitors of kras g12c protein and uses thereof |
| CN113880827B (zh) | 2020-07-03 | 2024-10-01 | 苏州闻天医药科技有限公司 | 一种用于抑制krasg12c突变蛋白的化合物及其制备方法和用途 |
| AU2021331492A1 (en) * | 2020-08-28 | 2023-04-13 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| US20240166660A1 (en) | 2021-01-15 | 2024-05-23 | Beigene Switzerland Gmbh | Kras g12c inhibitors |
| WO2022184178A1 (en) | 2021-03-05 | 2022-09-09 | Jacobio Pharmaceuticals Co., Ltd. | Kras g12d inhibitors |
| JP2024510207A (ja) * | 2021-03-12 | 2024-03-06 | ブリストル－マイヤーズ スクイブ カンパニー | Ｋｒａｓ阻害剤 |
| WO2022261154A1 (en) * | 2021-06-09 | 2022-12-15 | Eli Lilly And Company | Substituted fused azines as kras g12d inhibitors |
| WO2023061294A1 (zh) | 2021-10-13 | 2023-04-20 | 再鼎医药(上海)有限公司 | 含氮杂环类衍生物调节剂、其制备方法及应用 |
-
2023
- 2023-03-24 JP JP2024556680A patent/JP7676677B2/ja active Active
- 2023-03-24 KR KR1020247035268A patent/KR102847563B1/ko active Active
- 2023-03-24 WO PCT/US2023/016257 patent/WO2023183585A1/en not_active Ceased
- 2023-03-24 AU AU2023241055A patent/AU2023241055A1/en active Pending
- 2023-03-24 MX MX2024011631A patent/MX2024011631A/es unknown
- 2023-03-24 CN CN202380030401.9A patent/CN119095853A/zh active Pending
- 2023-03-24 IL IL315782A patent/IL315782A/en unknown
- 2023-03-24 EP EP23723097.4A patent/EP4499233A1/en active Pending
- 2023-03-24 CA CA3246810A patent/CA3246810A1/en active Pending
- 2023-03-24 KR KR1020257020079A patent/KR20250093430A/ko active Pending
- 2023-03-24 US US18/189,713 patent/US12351591B2/en active Active
- 2023-03-24 PE PE2024001867A patent/PE20251071A1/es unknown
- 2023-03-25 TW TW113108193A patent/TW202438502A/zh unknown
- 2023-03-25 TW TW112111395A patent/TWI852436B/zh active
-
2024
- 2024-09-17 CO CONC2024/0012604A patent/CO2024012604A2/es unknown
- 2024-09-20 DO DO2024000186A patent/DOP2024000186A/es unknown
- 2024-09-25 CL CL2024002874A patent/CL2024002874A1/es unknown
-
2025
- 2025-04-30 JP JP2025075148A patent/JP2025118729A/ja active Pending
- 2025-05-29 US US19/222,746 patent/US20250289830A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3246810A1 (en) | 2023-09-28 |
| JP2025512811A (ja) | 2025-04-22 |
| US20250289830A1 (en) | 2025-09-18 |
| US12351591B2 (en) | 2025-07-08 |
| DOP2024000186A (es) | 2024-10-31 |
| MX2024011631A (es) | 2024-09-30 |
| JP2025118729A (ja) | 2025-08-13 |
| KR20240160650A (ko) | 2024-11-11 |
| CL2024002874A1 (es) | 2024-12-20 |
| CO2024012604A2 (es) | 2024-12-09 |
| CN119095853A (zh) | 2024-12-06 |
| WO2023183585A1 (en) | 2023-09-28 |
| TW202404572A (zh) | 2024-02-01 |
| KR102847563B1 (ko) | 2025-08-20 |
| IL315782A (en) | 2024-11-01 |
| JP7676677B2 (ja) | 2025-05-14 |
| TWI852436B (zh) | 2024-08-11 |
| US20240043451A1 (en) | 2024-02-08 |
| EP4499233A1 (en) | 2025-02-05 |
| AU2023241055A1 (en) | 2024-10-10 |
| KR20250093430A (ko) | 2025-06-24 |
| TW202438502A (zh) | 2024-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20251071A1 (es) | Inhibidores de kras | |
| PE20230238A1 (es) | Inhibidores de kras g12c | |
| PE20251288A1 (es) | Compuestos heterociclicos como inmunomoduladores | |
| PE20252237A1 (es) | Inhibidores macrociclicos de kras y metodos de uso | |
| PE20212303A1 (es) | Inhibidores aza-heterobiciclicos de mat2a y metodos de uso en el tratamiento de cancer | |
| DOP2018000187A (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
| PE20250123A1 (es) | Inhibidores de cdk2 | |
| AR125425A1 (es) | Inhibidores de proteina tirosina fosfatasa y sus metodos de uso | |
| CL2022000736A1 (es) | Moduladores de sting (estimulador de genes de interferón) | |
| PE20250843A1 (es) | Inhibidores macrociclicos de kras para el tratamiento de cancer | |
| NZ543897A (en) | Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases | |
| EA201070523A1 (ru) | Производные фталазинона | |
| AR043508A1 (es) | 1-amino 1-h-imidazoquinolinas y su uso como inmunomoduladores | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| AR065499A1 (es) | Inhibidores de serino proteasas.composiciones farmaceuticas | |
| AR035216A1 (es) | Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios | |
| CL2023003652A1 (es) | Nuevos profármacos y conjugados de dimetiltriptamina | |
| AR066528A1 (es) | Peptidos inhibidores de la replicacion del virus de la hepatitis c | |
| AR038882A1 (es) | Compuestos que modulan la actividad de ppar y composicion farmaceutica que los contiene | |
| DOP2005000046A (es) | Compuestos de acido alfa arilo o heteroaril metil beta piperidino propanoico como antagonistas del receptor orl1 | |
| AR129339A1 (es) | Inhibidores de parg | |
| PE20081113A1 (es) | Inhibidores virales policiclicos | |
| PE20251706A1 (es) | Compuestos de urea triciclica como inhibidores de v617f de jak2 | |
| ES2531084T3 (es) | Proceso para la preparación de 2-cianopirrolidinas n-sustituidas | |
| AR128418A1 (es) | Inhibidores de la proteína tirosina fosfatasa y usos de estos |